Barclays Reaffirms Their Hold Rating on Mazor Robotics

By Carrie Williams

Barclays analyst Matthew Taylor maintained a Hold rating on Mazor Robotics (NASDAQ: MZOR) on October 9 and set a price target of $34. The company’s shares opened today at $54.05, close to its 52-week high of $55.66.

According to TipRanks.com, Taylor is a 4-star analyst with an average return of 7.3% and a 65.1% success rate. Taylor covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Baxter International.

Currently, the analyst consensus on Mazor Robotics is Moderate Buy and the average price target is $44, representing a -18.6% downside.

In a report issued on October 5, Needham also reiterated a Hold rating on the stock.

Based on Mazor Robotics’ latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $16.27 million and GAAP net loss of $3.87 million. In comparison, last year the company earned revenue of $7.77 million and had a GAAP net loss of $5.32 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Mazor Robotics Ltd. is a medical device company, which engages in the development and marketing of innovative surgical guidance systems and complementary products. It specializes in robotic, computerized and imaging-based systems, primarily in the field of spine surgery.